Metastatic renal cancer: sunitinib rechallenge feasible, safe

  • Nachbargauer S & et al.
  • Clin Genitourin Cancer
  • 4 Dec 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Sunitinib rechallenge is feasible in later lines in patients with metastatic renal cell carcinoma (mRCC) with an acceptable safety profile.

Why this matters

  • Sunitinib rechallenge can improve outcomes as an alternative treatment option in later lines when novel therapies are not available.

Study design

  • Retrospective study of 31 patients with mRCC who underwent sunitinib rechallenge and received sunitinib in ≥2 different treatment lines (upfront and rechallenge) during 2010-2017.
  • Primary outcome: treatment duration on sunitinib rechallenge.
  • Funding: None disclosed.

Key results

  • Median time between upfront and rechallenge dose was 8.9 months.
  • During sunitinib rechallenge and upfront therapy:
    • Median treatment duration was 7.2 (95% CI, 4.1-10.3) months and 17.8 (95% CI, 5.2-47.3) months, respectively.
    • Median PFS was 5.6 (95% CI, 3.0-8.2) months and 14.2 (95% CI, 1.6-35.8) months, respectively.
    • Median OS was 14.7 (95% CI, 9.4-20.0) months and 57.9 (95% CI, 48.8-66.9) months, respectively.
    • Objective response rate was 16% and 34%, respectively.
  • Most common adverse events overall were fatigue, hypertension, diarrhea, and nausea.
  • Most common grade 3-4 toxicity with rechallenge was fatigue, and with upfront sunitinib was hypertension.

Limitations

  • Single-center study.
  • Small number of patients.